Comparing two treatments for metastatic hormone-sensitive prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness and safety of combining Rezvilutamide with androgen deprivation therapy (ADT) and docetaxel against Rezvilutamide and ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The study aims to determine if the addition of chemotherapy improves overall survival in this patient population. Participants will be males aged 40 to 80 years with confirmed prostate adenocarcinoma and high tumor burden, who are eligible for ADT and docetaxel. The trial will assess various laboratory parameters to ensure participant safety and eligibility.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Males aged ≥40 years and ≤80 years.
2. Histologically or cytologically confirmed prostate adenocarcinoma.
3. Metastatic disease.
4. Eligible for ADT and Docetaxel.
5. Started or not started first-generation androgen deprivation therapy (ADT), but not exceeding 12 weeks before randomization.
6. ECOG score of 0 or 1.
7. Laboratory tests meet the following requirements:

   * Hematology: neutrophils ≥1.5×10\^9/L, platelets ≥100×10\^9/L, hemoglobin ≥9g/dL.
   * Renal function: serum creatinine ≤1.5× upper limit of normal (ULN).
   * Liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5× ULN, total bilirubin (TBIL) ≤1.5× ULN.
   * Coagulation function: international normalized ratio (INR) \<1.5.
8. Study subjects: Patients with mHSPC have a confirmed pathology of prostate adenocarcinoma with high tumor burden, which is defined by having at least one of the following conditions:

1\) Bone scan showing ≥4 bone metastatic lesions (with at least one site outside the pelvis or spine).

2\) CT/MRI revealing visceral metastatic lesions (excluding lymph nodes).

Exclusion Criteria:

Patients who meet any of the following criteria are not eligible to participate in this study:

1. Prior use of LHRH agonists/antagonists; second-generation androgen receptor (AR) inhibitors such as enzalutamide, ARN-509, darolutamide (ODM-201), or other investigational AR inhibitors; CYP17 enzyme inhibitors such as abiraterone acetate or oral ketoconazole for anti-tumor treatment of prostate cancer; chemotherapy or immunotherapy for prostate cancer prior to randomization.
2. Received radiation therapy/radiopharmaceutical treatment within 2 weeks before randomization.
3. Any of the following conditions within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary artery/peripheral artery bypass surgery, congestive heart failure (New York Heart Association class III or IV).
4. Previous malignancy, except adequately treated basal cell carcinoma or squamous cell carcinoma of the skin or superficial bladder cancer not invading the deeper muscle layer (i.e., pTis, pTa, and pT1) and any other cancer in complete remission for at least 5 years before randomization.
5. Gastrointestinal diseases or procedures that are expected to significantly interfere with the absorption of study treatment.
6. Inability to take oral medication.

Where it's running

• Urology dpt, First Affiliated Hospital of Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Principal investigator: Lixxin Hua — Urology Dpt, First Affiliated Hospital of Nanjing Medical University
• Study coordinator: Shangqian Wang, M.D., Ph.D.
• Email: wsq5501@126.com
• Phone: +862568303186

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• JANX013 and JANX007 combo in advanced prostate cancer

  A first-in-human study will test JANX013 together with JANX007 to see if this combination is safe and tolerable in adults with metastatic castration-resistant prostate cancer.

  Recruiting Phase 1 Janux Therapeutics · Nashville, Tennessee · NCT07813637

• PSMA PET-Staged Progression-Directed Radiotherapy for Limited Prostate Cancer Progression

  A real-world registry tests how well comprehensive progression-directed radiotherapy works for men with metastatic prostate cancer who show a small number of progressing lesions while on systemic therapy.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07691697

• Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer

  This registry follows men with new, limited metastatic prostate cancer who receive targeted radiotherapy to the prostate and all visible metastases to see how they do over time in real-world care.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07686016

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• First-in-human imaging test of the GRPR-targeted theranostic pair for advanced breast or prostate cancer

  This early feasibility study tests a GRPR-targeted imaging agent for PET and a low-dose radiopharmaceutical for SPECT in adults with advanced breast or prostate cancer to see if it is safe and can image tumors.

  Recruiting Early Phase 1 Integrated Haematology and Oncology Network · Perth, Western Australia · NCT07608848

• Combined treatment approach in metastatic prostate cancer using AZD2265 (FPI-2265) with palacaparib or docetaxel

  This study tests how AZD2265 (FPI-2265) with or without palacaparib or docetaxel works in men with metastatic castration-resistant prostate cancer who have already tried AR pathway inhibitors.

  Recruiting at 3 sites Phase 1/2 AstraZeneca · Duarte, California and 37 other locations · NCT07590934

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.